Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry

B. Bikdeli, D. Jiménez, P. Demelo-Rodriguez, F. Galeano-Valle, JA. Porras, R. Barba, C. Ay, R. Malý, A. Braester, E. Imbalzano, V. Rosa, R. Lecumberri, C. Siniscalchi, Á. Fidalgo, S. Ortiz, M. Monreal, . For The Riete Investigators

. 2022 ; 14 (2) : . [pub] 20220118

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011304

BACKGROUND: Venous thromboembolism (VTE)-including deep vein thrombosis, pulmonary embolism, and cerebral venous sinus thrombosis (CVST)-may occur early after vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We sought to describe the site, clinical characteristics, and outcomes of VTE after vaccination against SARS-CoV-2. METHODS: In a prospective study using the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) platform, patients with VTE 4-30 days after vaccination against SARS-CoV-2 (1 February 2021 through 30 April 2021) were included. VTE patients recruited from the same centers into RIETE in the same months in 2018-2019 were selected as the reference group. All-cause mortality and major bleeding were the main study outcomes. RESULTS: As of 30 April 2020, 102 patients with post-vaccination VTEs had been identified (28 after adenovirus-based vaccination [ChAdOx1 nCov-19; AstraZeneca] and 74 after mRNA-based vaccination [mRNA-1273; Moderna, and BNT162b2; Pfizer]). Compared with 911 historical controls, patients with VTE after adenovirus-based vaccination more frequently had CVST (10.7% vs. 0.4%, p < 0.001) or thrombosis at multiple sites (17.9% vs. 1.3%, p < 0.001), more frequently had thrombocytopenia (40.7% vs. 14.7%, p < 0.001), and had higher 14-day mortality (14.3% vs. 0.7%; odds ratio [OR]: 25.1; 95% confidence interval [CI]: 6.7-94.9) and major bleeding rates (10.3% vs. 1.0%, OR: 12.03, 95% CI: 3.07-47.13). The site of thrombosis, accompanying thrombocytopenia, and 14-day mortality rates were not significantly different for patients with VTE after mRNA-based vaccination, compared with historical controls. CONCLUSIONS: Compared with historical controls, VTE after adenovirus-based vaccination against SARS-CoV-2 is accompanied by thrombocytopenia, occurs in unusual sites, and is associated with worse clinical outcomes.

Cardiovascular Medicine Division Brigham and Women's Hospital Harvard Medical School Boston MA 02115 USA

Center for Biomedical Research Network on Cardiovascular Diseases Instituto de Salud Carlos 3 28029 Madrid Spain

Center for Outcomes Research and Evaluation Yale School of Medicine New Haven CT 06510 USA

Centro de Investigación Biomédica en Red de Enfermedades Respiratorias 28029 Madrid Spain

Clinical Trials Center Cardiovascular Research Foundation New York NY 10019 USA

Department of Angiology Azienda Ospedaliera Universitaria 43126 Parma Italy

Department of Cardiovascular Medicine 1 Faculty of Medicine Charles University Prague University Hospital Hradec Kralove 500 05 Hradec Kralove Czech Republic

Department of Clinical and Experimental Medicine A O U Policlinico G Martino 98124 Messina Italy

Department of Haematology Azrieli Faculty of Medicine Bar Ilan University 13195 Safed Israel

Department of Haematology Clínica Universidad de Navarra 31008 Pamplona Spain

Department of Internal Medicine Hospital General Universitario Gregorio Marañón 28007 Madrid Spain

Department of Internal Medicine Hospital Rey Juan Carlos 28933 Madrid Spain

Department of Internal Medicine Hospital Universitario de Salamanca 37007 Salamanca Spain

Department of Internal Medicine Hospital Universitario Joan XXIII de Tarragona 43005 Tarragona Spain

Department of Internal Medicine Hospital Universitario Virgen de Arrixaca 30120 Murcia Spain

Department of Medicine 1 Clinical Division of Haematology and Haemostaseology Medical University of Vienna 1090 Vienna Austria

Department of Statistics Universidad Autónoma Madrid 28049 Madrid Spain

Faculty of Health Sciences Universidad Católica San Antonio de Murcia 30107 Murcia Spain

Instituto de investigación sanitaria Gregorio Marañón 28007 Madrid Spain

Respiratory Department Hospital Ramón y Cajal and Universidad de Alcalá 28034 Madrid Spain

S and H Medical Science Service 28034 Madrid Spain

School of Medicine Universidad Complutense de Madrid 28040 Madrid Spain

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011304
003      
CZ-PrNML
005      
20220506130952.0
007      
ta
008      
220425s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/v14020178 $2 doi
035    __
$a (PubMed)35215771
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bikdeli, Behnood $u Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA $u Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, CT 06510, USA $u Clinical Trials Center, Cardiovascular Research Foundation, New York, NY 10019, USA
245    10
$a Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry / $c B. Bikdeli, D. Jiménez, P. Demelo-Rodriguez, F. Galeano-Valle, JA. Porras, R. Barba, C. Ay, R. Malý, A. Braester, E. Imbalzano, V. Rosa, R. Lecumberri, C. Siniscalchi, Á. Fidalgo, S. Ortiz, M. Monreal, . For The Riete Investigators
520    9_
$a BACKGROUND: Venous thromboembolism (VTE)-including deep vein thrombosis, pulmonary embolism, and cerebral venous sinus thrombosis (CVST)-may occur early after vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We sought to describe the site, clinical characteristics, and outcomes of VTE after vaccination against SARS-CoV-2. METHODS: In a prospective study using the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) platform, patients with VTE 4-30 days after vaccination against SARS-CoV-2 (1 February 2021 through 30 April 2021) were included. VTE patients recruited from the same centers into RIETE in the same months in 2018-2019 were selected as the reference group. All-cause mortality and major bleeding were the main study outcomes. RESULTS: As of 30 April 2020, 102 patients with post-vaccination VTEs had been identified (28 after adenovirus-based vaccination [ChAdOx1 nCov-19; AstraZeneca] and 74 after mRNA-based vaccination [mRNA-1273; Moderna, and BNT162b2; Pfizer]). Compared with 911 historical controls, patients with VTE after adenovirus-based vaccination more frequently had CVST (10.7% vs. 0.4%, p < 0.001) or thrombosis at multiple sites (17.9% vs. 1.3%, p < 0.001), more frequently had thrombocytopenia (40.7% vs. 14.7%, p < 0.001), and had higher 14-day mortality (14.3% vs. 0.7%; odds ratio [OR]: 25.1; 95% confidence interval [CI]: 6.7-94.9) and major bleeding rates (10.3% vs. 1.0%, OR: 12.03, 95% CI: 3.07-47.13). The site of thrombosis, accompanying thrombocytopenia, and 14-day mortality rates were not significantly different for patients with VTE after mRNA-based vaccination, compared with historical controls. CONCLUSIONS: Compared with historical controls, VTE after adenovirus-based vaccination against SARS-CoV-2 is accompanied by thrombocytopenia, occurs in unusual sites, and is associated with worse clinical outcomes.
650    _2
$a vakcína firmy Moderna proti COVID-19 $x aplikace a dávkování $x škodlivé účinky $7 D000090983
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a vakcína BNT162 $x aplikace a dávkování $x škodlivé účinky $7 D000090982
650    _2
$a COVID-19 $x prevence a kontrola $7 D000086382
650    _2
$a ChAdOx1 nCoV-19 $x aplikace a dávkování $x škodlivé účinky $7 D000090985
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a hodnocení výsledků zdravotní péče $7 D017063
650    _2
$a prospektivní studie $7 D011446
650    12
$a registrace $7 D012042
650    _2
$a rizikové faktory $7 D012307
650    _2
$a trombocytopenie $x etiologie $7 D013921
650    _2
$a časové faktory $7 D013997
650    _2
$a vakcinace $x škodlivé účinky $x mortalita $7 D014611
650    _2
$a žilní tromboembolie $x etiologie $7 D054556
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jiménez, David $u Respiratory Department, Hospital Ramón y Cajal and Universidad de Alcalá (IRYCIS), 28034 Madrid, Spain $u Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain $1 https://orcid.org/0000000245717721
700    1_
$a Demelo-Rodriguez, Pablo $u Department of Internal Medicine, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain $u Instituto de investigación sanitaria Gregorio Marañón (IiSGM), 28007 Madrid, Spain $u School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain $1 https://orcid.org/0000000230964711
700    1_
$a Galeano-Valle, Francisco $u Department of Internal Medicine, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain $u Instituto de investigación sanitaria Gregorio Marañón (IiSGM), 28007 Madrid, Spain $u School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain $1 https://orcid.org/0000000313216866
700    1_
$a Porras, José Antonio $u Department of Internal Medicine, Hospital Universitario Joan XXIII de Tarragona, 43005 Tarragona, Spain
700    1_
$a Barba, Raquel $u Department of Internal Medicine, Hospital Rey Juan Carlos, 28933 Madrid, Spain
700    1_
$a Ay, Cihan $u Department of Medicine I - Clinical Division of Haematology and Haemostaseology, Medical University of Vienna, 1090 Vienna, Austria $1 https://orcid.org/0000000326079717
700    1_
$a Malý, Radovan $u Department of Cardiovascular Medicine I, Faculty of Medicine, Charles University in Prague, University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000291997883
700    1_
$a Braester, Andrei $u Department of Haematology, Azrieli Faculty of Medicine, Bar-Ilan University, 13195 Safed, Israel
700    1_
$a Imbalzano, Egidio $u Department of Clinical and Experimental Medicine, A.O.U Policlinico "G. Martino", 98124 Messina, Italy $1 https://orcid.org/0000000326565467
700    1_
$a Rosa, Vladimir $u Department of Internal Medicine, Hospital Universitario Virgen de Arrixaca, 30120 Murcia, Spain $1 https://orcid.org/0000000150396638
700    1_
$a Lecumberri, Ramón $u Department of Haematology, Clínica Universidad de Navarra, 31008 Pamplona, Spain $u Center for Biomedical Research Network on Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain
700    1_
$a Siniscalchi, Carmine $u Department of Angiology, Azienda Ospedaliera Universitaria, 43126 Parma, Italy
700    1_
$a Fidalgo, Ángeles $u Department of Internal Medicine, Hospital Universitario de Salamanca, 37007 Salamanca, Spain $1 https://orcid.org/0000000165669029
700    1_
$a Ortiz, Salvador $u Department of Statistics, Universidad Autónoma Madrid, 28049 Madrid, Spain $u S&H Medical Science Service, 28034 Madrid, Spain $1 https://orcid.org/0000000187831920
700    1_
$a Monreal, Manuel $u Faculty of Health Sciences, Universidad Católica San Antonio de Murcia (UCAM), 30107 Murcia, Spain $1 https://orcid.org/0000000204940767
700    1_
$a For The Riete Investigators,
773    0_
$w MED00177099 $t Viruses $x 1999-4915 $g Roč. 14, č. 2 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35215771 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130944 $b ABA008
999    __
$a ok $b bmc $g 1789074 $s 1162502
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 2 $e 20220118 $i 1999-4915 $m Viruses $n Viruses $x MED00177099
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace